Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 98 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bimatoprost Clear all
Recruiting Phase 3 Interventional

A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study

NCT07661329
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
Interventions
Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®)
Drug
Lead sponsor
YS Life Science Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Beverly Hills, California • Inglewood, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

NCT05729594
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bimatoprost Ophthalmic
Drug
Lead sponsor
Laboratoires Thea
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

NCT02537015
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost
Drug
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 3, 2026, 6:49 AM EDT
Completed No phase listed Observational Results available

An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes

NCT01623479
View directory record Official record
Conditions
Eyelash Hypotrichosis
Interventions
bimatoprost 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 3, 2026, 6:49 AM EDT
Completed No phase listed Observational Results available

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

NCT00716742
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bimatoprost Ocular Insert Pharmacokinetic Study

NCT02444767
View directory record Official record
Conditions
Healthy Volunteers
Interventions
13mg Bimatoprost Ocular Insert
Drug
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows

NCT01891487
View directory record Official record
Conditions
Hypotrichosis
Interventions
Track A, Track B
Drug
Lead sponsor
ATS Clinical Research
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT00809848
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%, bimatoprost ophthalmic solution 0.03%, AGN-210669 vehicle ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Sep 3, 2026, 6:49 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

NCT02676310
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
Bimatoprost
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Austin, Texas • College Station, Texas • Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 3, 2026, 6:49 AM EDT
Recruiting Early Phase 1 Interventional

Bimatoprost as a Treatment for Graves' Orbitopathy

NCT03708627
View directory record Official record
Conditions
Graves Ophthalmopathy
Interventions
Bimatoprost Ophthalmic
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 6:49 AM EDT
Not listed Phase 4 Interventional

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma

NCT04981886
View directory record Official record
Conditions
Normal Tension Glaucoma
Interventions
Netarsudil Ophthalmic, Bimatoprost Ophthalmic
Drug
Lead sponsor
Salus University
Other
Eligibility
21 Years to 89 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Vestal, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

NCT01863953
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Fixed-Combination Bimatoprost/Brimonidine, Bimatoprost Ophthalmic Solution 0.01%, Vehicle Ophthalmic Solution, Brimonidine Tartrate Ophthalmic Solution 0.2%
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 4 Interventional Results available

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

NCT01448525
View directory record Official record
Conditions
Hypotrichosis
Interventions
bimatoprost ophthalmic solution 0.03%, bimatoprost vehicle solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT02250651
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Bimatoprost in the Treatment of Eyelash Hypotrichosis

NCT01698554
View directory record Official record
Conditions
Idiopathic Eyelash Hypotrichosis
Interventions
bimatoprost formulation A solution, bimatoprost solution 0.03 %, vehicle of bimatoprost formulation A solution, vehicle of bimatoprost solution 0.03 %
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin

NCT00907426
View directory record Official record
Conditions
Hypotrichosis
Interventions
Bimatoprost 0.03% solution, Vehicle solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

NCT05397600
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Ophthalmic
Drug
Lead sponsor
Laboratoires Thea
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
56
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 4 Interventional

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

NCT00847483
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
40
States / cities
Bellflower, California • Inglewood, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 4 Interventional

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

NCT00348023
View directory record Official record
Conditions
Glaucoma
Interventions
Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2007 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT05335122
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

NCT00541242
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
bimatoprost 0.03% eye drops, latanoprost 0.005% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Study of LL-BMT1 in Patients With Elevated Intraocular Pressure

NCT04747808
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
LL-BMT1
Drug
Lead sponsor
MediPrint Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT01177098
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 3, 2026, 6:49 AM EDT